103 related articles for article (PubMed ID: 14532780)
1. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
[TBL] [Abstract][Full Text] [Related]
2. Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.
Washington SL; Jeong CW; Lonergan PE; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
JAMA Netw Open; 2020 Dec; 3(12):e2031349. PubMed ID: 33369661
[TBL] [Abstract][Full Text] [Related]
3. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.
Cooperberg MR; Lubeck DP; Meng MV; Mehta SS; Carroll PR
J Clin Oncol; 2004 Jun; 22(11):2141-9. PubMed ID: 15169800
[TBL] [Abstract][Full Text] [Related]
4. Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer.
Hu S; Chang CP; Snyder J; Deshmukh V; Newman M; Date A; Galvao C; Porucznik CA; Gren LH; Sanchez A; Lloyd S; Haaland B; O'Neil B; Hashibe M
JCO Clin Cancer Inform; 2023 Sep; 7():e2300083. PubMed ID: 37988640
[TBL] [Abstract][Full Text] [Related]
5. Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study.
Hoffman RM; Mott SL; McDowell BD; Anand ST; Nepple KG
Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):100-108. PubMed ID: 34108645
[TBL] [Abstract][Full Text] [Related]
6. Current clinical presentation and treatment of localized prostate cancer in the United States.
Mahmood U; Levy LB; Nguyen PL; Lee AK; Kuban DA; Hoffman KE
J Urol; 2014 Dec; 192(6):1650-6. PubMed ID: 24931803
[TBL] [Abstract][Full Text] [Related]
7. Predicting the 10-year risk of death from other causes in men with localized prostate cancer using patient-reported factors: Development of a tool.
Frendl DM; FitzGerald G; Epstein MM; Allison JJ; Sokoloff MH; Ware JE
PLoS One; 2020; 15(12):e0240039. PubMed ID: 33284845
[TBL] [Abstract][Full Text] [Related]
8. Trends in treatments for prostate cancer in the United States, 2010-2015.
Wang J; Xia HH; Zhang Y; Zhang L
Am J Cancer Res; 2021; 11(5):2351-2368. PubMed ID: 34094691
[TBL] [Abstract][Full Text] [Related]
9. National Trends in Management of Newly Diagnosed Prostate Cancer.
Maganty A; Kaufman SR; Oerline MK; Lai LY; Caram MEV; Shahinian VB; Hollenbeck BK
Clin Genitourin Cancer; 2024 Apr; 22(2):10-17. PubMed ID: 37468340
[TBL] [Abstract][Full Text] [Related]
10. Active surveillance should be considered for select men with Grade Group 2 prostate cancer.
Pekala KR; Bergengren O; Eastham JA; Carlsson SV
BMC Urol; 2023 Sep; 23(1):152. PubMed ID: 37777716
[TBL] [Abstract][Full Text] [Related]
11. Development of a novel, clinically relevant anoikis-related gene signature to forecast prognosis in patients with prostate cancer.
Liu X; Wang K
Front Genet; 2023; 14():1166668. PubMed ID: 37719710
[No Abstract] [Full Text] [Related]
12. Cancer-associated fibroblast-derived gene signatures predict radiotherapeutic survival in prostate cancer patients.
Zhang R; Liu F
J Transl Med; 2022 Oct; 20(1):453. PubMed ID: 36195908
[TBL] [Abstract][Full Text] [Related]
13. Development of Mobile Application for Dynamically Monitoring the Risk of Prostate Cancer and Clinicopathology.
Wang H; Chen L; Zhou J; Tai S; Liang C
Cancer Manag Res; 2020; 12():12175-12184. PubMed ID: 33273854
[TBL] [Abstract][Full Text] [Related]
14. Factors underlying treatment decision-making for localized prostate cancer in the U.S. and Canada: A scoping review using principal component analysis.
Andkhoie M; Meyer D; Szafron M
Can Urol Assoc J; 2019 Jul; 13(7):E220-E225. PubMed ID: 30472985
[TBL] [Abstract][Full Text] [Related]
15. Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study.
Awasthi S; Gerke T; Park JY; Asamoah FA; Williams VL; Fink AK; Balkrishnan R; Lee DI; Malkowicz SB; Lal P; Dhillon J; Pow-Sang JM; Rebbeck TR; Yamoah K
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):570-577. PubMed ID: 30413401
[TBL] [Abstract][Full Text] [Related]
16. Active surveillance for low-risk localized prostate cancer: what do men and their partners think?
Mallapareddi A; Ruterbusch J; Reamer E; Eggly S; Xu J
Fam Pract; 2017 Feb; 34(1):90-97. PubMed ID: 28034917
[TBL] [Abstract][Full Text] [Related]
17. PIVOT and the challenges of localized prostate cancer care.
Weinberg AE; Brooks JD
Transl Androl Urol; 2012 Sep; 1(3):141-3. PubMed ID: 26816701
[No Abstract] [Full Text] [Related]
18. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer.
Kwon YS; Han CS; Yu JW; Kim S; Modi P; Davis R; Park JH; Lee P; Ha YS; Kim WJ; Kim IY
Clin Genitourin Cancer; 2016 Feb; 14(1):e1-8. PubMed ID: 26341038
[TBL] [Abstract][Full Text] [Related]
19. PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer.
El-Shater Bosaily A; Parker C; Brown LC; Gabe R; Hindley RG; Kaplan R; Emberton M; Ahmed HU;
Contemp Clin Trials; 2015 May; 42():26-40. PubMed ID: 25749312
[TBL] [Abstract][Full Text] [Related]
20. Conditional probability of reclassification in an active surveillance program for prostate cancer.
Alam R; Carter HB; Landis P; Epstein JI; Mamawala M
J Urol; 2015 Jun; 193(6):1950-5. PubMed ID: 25572035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
